Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1009MR)

This product GTTS-WQ1009MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1009MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13814MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ7019MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ1084MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ13602MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ6703MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ3964MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ8612MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ14275MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW